Parotid Tumors: Increasing prevalence of cancer is likely to drive the growth of the global market at CAGR of 7.90% during 2023 to 2030

Pune, India, May 2023 /MRFR Press Release/- Market Research Future (MRFR) announces the publication of its research report – Global Parotid Tumors market 2023-2030

Market Highlights

Global Parotid Tumors market is expected to grow at a CAGR of 7.90% during the forecasted period (2023-2030) and is expected to reach USD 7.54 Billion by 2030.

Parotid Tumors are abnormal growths within the parotid gland also known as the salivary gland. There are two Parotid glands on either side of the face. Mostly the growths or tumors are slow growing and benign (non-cancerous), but seldom they can be malignant (cancerous).

Regional Analysis

The Americas dominate the global Parotid Tumors market owing to the rising incidence of different types of cancer, growing prevalence of liver disorders especially liver cirrhosis and rising number of individuals consuming alcohol is likely to drive the growth of parotid tumors market. Additionally, market players focusing on advanced technologies and growing government initiatives is propelling the growth of the market.

Europe accounts for the second largest market due to increasing incidence of liver cirrhosis, and other liver disorders. Additionally, increasing government support and increasing healthcare expenditure along with rising demand for technologically advanced devices for the surgical procedures is driving the growth of overall medical device market.

Asia Pacific is the fastest growing market for the Parotid Tumors whose growth is attributed to rising population which in turn increases the overall patient population, increasing the prevalence of people suffering from cancer liver disorders and rising consumption of alcohol among masses. Additionally, increasing healthcare expenditure and demand for new treatment options for diseases fuel the market growth. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and increasing demand for diagnostic services.

On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to healthcare and lack of awareness among individuals. In the Middle East, the growth of the market is driven by increasing availability of new and advanced diagnostic and treatment methods for various chronic diseases.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Parotid Tumors Market Research Report

Segmentation

The global Parotid Tumors infection market is segmented on the basis of type, treatment, diagnosis and end users.

On the basis of the type Pleomorphic Adenoma, Warthin's Tumor and Cancerous/Malignant Tumor. 

On the basis of treatment, the market is segmented into Parotidectomy, Removal of Lymph Node, Reconstructive Surgery, Radiation Therapy, and Chemotherapy.

 On the basis of diagnosis, the market is segmented into X-ray, CT scan, MRI, Ultrasound, FNAC (Fine Needle Aspiration Cytology), Sialography, and others. 

On the basis of the end users, the market is segmented into hospitals, Specialty centers, and Research centers.

Key Players

Some of the players in the Parotid Tumors market are Eli Lilly & Co, Bayer AG, Merck & Co. Inc., Pfizer Inc., Bristol-Myers Squibb, Janssen Global Services, LLC, Hoffmann-La Roche Ltd, and Novartis AG.